NO20032360L - EP4 reseptor selektive agonister for behandling av osteoporose - Google Patents
EP4 reseptor selektive agonister for behandling av osteoporoseInfo
- Publication number
- NO20032360L NO20032360L NO20032360A NO20032360A NO20032360L NO 20032360 L NO20032360 L NO 20032360L NO 20032360 A NO20032360 A NO 20032360A NO 20032360 A NO20032360 A NO 20032360A NO 20032360 L NO20032360 L NO 20032360L
- Authority
- NO
- Norway
- Prior art keywords
- osteoporosis
- treatment
- selective agonists
- receptor selective
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25327500P | 2000-11-27 | 2000-11-27 | |
| PCT/IB2001/002073 WO2002042268A2 (en) | 2000-11-27 | 2001-11-05 | Ep4 receptor selective agonists in the treatment of osteoporosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20032360D0 NO20032360D0 (no) | 2003-05-26 |
| NO20032360L true NO20032360L (no) | 2003-07-23 |
Family
ID=22959588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20032360A NO20032360L (no) | 2000-11-27 | 2003-05-26 | EP4 reseptor selektive agonister for behandling av osteoporose |
Country Status (41)
| Country | Link |
|---|---|
| US (3) | US6552067B2 (da) |
| EP (1) | EP1339678B1 (da) |
| JP (2) | JP3984164B2 (da) |
| KR (1) | KR20030053063A (da) |
| CN (1) | CN1476429A (da) |
| AR (1) | AR035074A1 (da) |
| AT (1) | ATE374182T1 (da) |
| AU (1) | AU2002210848A1 (da) |
| BG (1) | BG107697A (da) |
| BR (1) | BR0115687A (da) |
| CA (1) | CA2429850C (da) |
| CY (1) | CY1106976T1 (da) |
| CZ (1) | CZ20031257A3 (da) |
| DE (1) | DE60130675T2 (da) |
| DK (1) | DK1339678T3 (da) |
| EA (1) | EA200300379A1 (da) |
| EC (1) | ECSP034623A (da) |
| EE (1) | EE200300246A (da) |
| ES (1) | ES2291361T3 (da) |
| GT (2) | GT200100238A (da) |
| HN (1) | HN2001000266A (da) |
| HU (1) | HUP0400807A2 (da) |
| IL (1) | IL155368A0 (da) |
| IS (1) | IS6775A (da) |
| MA (1) | MA26961A1 (da) |
| MX (1) | MXPA03004623A (da) |
| NO (1) | NO20032360L (da) |
| NZ (1) | NZ525164A (da) |
| OA (1) | OA12533A (da) |
| PA (1) | PA8533901A1 (da) |
| PE (1) | PE20020637A1 (da) |
| PL (1) | PL362030A1 (da) |
| PT (1) | PT1339678E (da) |
| SI (1) | SI1339678T1 (da) |
| SK (1) | SK5562003A3 (da) |
| SV (1) | SV2003000746A (da) |
| TN (1) | TNSN01166A1 (da) |
| TW (1) | TW200424170A (da) |
| UY (1) | UY27038A1 (da) |
| WO (1) | WO2002042268A2 (da) |
| ZA (1) | ZA200302803B (da) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK5562003A3 (en) * | 2000-11-27 | 2004-08-03 | Pfizer Prod Inc | EP4 receptor selective agonists in the treatment of osteoporosis |
| WO2003008377A1 (en) * | 2001-07-16 | 2003-01-30 | F. Hoffmann-La Roche Ag | Prostaglandin analogues_as ep4 receptor agonists |
| MXPA04000454A (es) | 2001-07-16 | 2004-03-18 | Hoffmann La Roche | Derivados de 2-pirrolidona como agonistas de prostanoides. |
| ATE500218T1 (de) * | 2001-07-23 | 2011-03-15 | Ono Pharmaceutical Co | Mittel zur behandlung von erkrankungen, die mit knochenschwund einhergehen, mit ep4-agonist als wirkstoff |
| US20040254230A1 (en) * | 2001-12-03 | 2004-12-16 | Ogidigben Miller J. | Method for treating ocular hypertension |
| WO2003074483A1 (fr) | 2002-03-05 | 2003-09-12 | Ono Pharmaceutical Co., Ltd. | Composes derives de 8 azaprostaglandine et medicaments contenant ceux-ci comme principe actif |
| BR0308493A (pt) * | 2002-03-18 | 2005-01-11 | Pfizer Prod Inc | Uso de agonistas de receptor seletivo de ep4 para o tratamento da insuficiência hepática, perda de permeabilidade do canal arterial, glaucoma ou hipertensão ocular |
| AU2003207900A1 (en) * | 2002-03-18 | 2003-09-29 | Pfizer Products Inc. | Methods of treatment with selective ep4 receptor agonists |
| US6573294B1 (en) | 2002-05-14 | 2003-06-03 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
| AU2003233731A1 (en) * | 2002-06-06 | 2003-12-22 | Xavier Billot | 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases |
| DE60334905D1 (de) * | 2002-06-06 | 2010-12-23 | Merck Frosst Canada Ltd | 1,5-disubstituierte pyrrolid-2-on-derivate zur verwendung als ep4 rezeptor agonisten zur behandlung von augenkrankheiten wie z.b. glaukom |
| CA2483555A1 (en) * | 2002-06-10 | 2003-12-18 | Applied Research Systems Ars Holding N.V. | Gamma lactams as prostaglandin agonists and use thereof |
| GB0219143D0 (en) * | 2002-08-16 | 2002-09-25 | Univ Leicester | Modified tailed oligonucleotides |
| PT1563846E (pt) | 2002-10-10 | 2012-11-13 | Ono Pharmaceutical Co | Promotores da produção de factores endógenos de reparação |
| WO2004037813A1 (en) * | 2002-10-25 | 2004-05-06 | Merck Frosst Canada & Co. | Pyrrolidin-2-on derivatives as ep4 receptor agonists |
| US7196082B2 (en) | 2002-11-08 | 2007-03-27 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
| CA2505127A1 (en) | 2002-11-08 | 2004-05-27 | James B. Doherty | Ophthalmic compositions for treating ocular hypertension |
| US7053085B2 (en) | 2003-03-26 | 2006-05-30 | Merck & Co. Inc. | EP4 receptor agonist, compositions and methods thereof |
| RU2311409C2 (ru) * | 2003-01-10 | 2007-11-27 | Ф.Хоффманн-Ля Рош Аг | Производные 2-пиперидона в качестве агонистов простагландина |
| JP4582456B2 (ja) * | 2003-01-21 | 2010-11-17 | 小野薬品工業株式会社 | ８−アザプロスタグランジン誘導体およびその医薬用途 |
| US7276531B2 (en) | 2003-03-03 | 2007-10-02 | Applied Research Systems Ars Holding N.V. | G-lactam derivatives as prostaglandin agonists |
| US6734201B1 (en) | 2003-06-02 | 2004-05-11 | Allergan, Inc. | 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents |
| US6734206B1 (en) | 2003-06-02 | 2004-05-11 | Allergan, Inc. | 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure |
| WO2005012232A2 (en) | 2003-07-18 | 2005-02-10 | Applied Research Systems Ars Holding N.V. | Hydrazide derivatives as prostaglandin receptors modulators |
| US7034051B2 (en) * | 2003-08-28 | 2006-04-25 | Adolor Corporation | Fused bicyclic carboxamide derivatives and methods of their use |
| EP1664011A4 (en) | 2003-09-02 | 2009-02-25 | Merck & Co Inc | OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA |
| US7494983B2 (en) | 2003-09-04 | 2009-02-24 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
| KR20060090801A (ko) | 2003-09-04 | 2006-08-16 | 머크 앤드 캄파니 인코포레이티드 | 고안압증 치료용 안용 조성물 |
| WO2005027931A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist |
| EP1696893A1 (en) * | 2003-12-17 | 2006-09-06 | Pfizer Products Incorporated | Continuous combination therapy with selective prostaglandin ep4, receptor agonists and an estrogen for the treatment of conditions that present with low bone mass. |
| US7169807B2 (en) * | 2004-04-09 | 2007-01-30 | Allergan, Inc. | 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists |
| WO2006020003A2 (en) | 2004-07-20 | 2006-02-23 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
| US7858650B2 (en) | 2004-10-22 | 2010-12-28 | Ono Pharmaceutical Co., Ltd. | Medicinal composition for inhalation |
| CA2585367A1 (en) * | 2004-10-26 | 2006-05-04 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin ep4 agonists |
| US7994195B2 (en) * | 2004-11-04 | 2011-08-09 | Allergan, Inc. | Therapeutic substituted piperidone compounds |
| AU2005304764B2 (en) | 2004-11-08 | 2012-07-12 | Allergan, Inc. | Substituted pyrrolidone compounds as EP4 agonists |
| US7101906B2 (en) * | 2004-11-16 | 2006-09-05 | Allergan, Inc. | 2,3,4-substituted cyclopentanones as therapeutic agents |
| US7183324B2 (en) | 2004-11-23 | 2007-02-27 | Allergan, Inc. | 2,3,4-substituted cyclopentanones as therapeutic agents |
| CN101133037B (zh) * | 2005-01-27 | 2012-05-09 | 旭化成制药株式会社 | 六元杂环化合物及其用途 |
| US7531533B2 (en) | 2005-01-27 | 2009-05-12 | Asahi Kasei Pharma Corporation | 6-Membered heterocyclic compound and use thereof |
| ATE515263T1 (de) * | 2005-05-06 | 2011-07-15 | Allergan Inc | Substituierte beta-lactame und deren verwendung in der medizin |
| US7772392B2 (en) | 2005-05-06 | 2010-08-10 | Allergan, Inc. | Therapeutic substituted β-lactams |
| US7893107B2 (en) * | 2005-11-30 | 2011-02-22 | Allergan, Inc. | Therapeutic methods using prostaglandin EP4 agonist components |
| KR100598678B1 (ko) * | 2006-02-15 | 2006-07-19 | (주)아이앤씨 | 수직형 대형 폐기물 파쇄기 |
| US20070232660A1 (en) * | 2006-04-04 | 2007-10-04 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin ep4 agonists |
| EP2094839B1 (en) | 2006-12-08 | 2020-02-05 | University of Rochester | Expansion of hematopoietic stem cells |
| CA2690273A1 (en) | 2006-12-18 | 2008-06-26 | Allergan, Inc. | Use of prostaglandin ep4 agonist for treating gastrointestinal disorders |
| US8507545B2 (en) | 2007-05-08 | 2013-08-13 | National University Corporation, Hamamatsu University School Of Medicine | Cytotoxic T cell activator comprising EP4 agonist |
| SI2155733T1 (sl) * | 2007-05-23 | 2012-12-31 | Allergan, Inc | Ciklični laktami za zdravljenje glavkoma ali zvišanega očesnega tlaka |
| US8063033B2 (en) * | 2008-01-18 | 2011-11-22 | Allergan, Inc. | Therapeutic beta-lactams |
| US8202855B2 (en) | 2008-03-04 | 2012-06-19 | Allergan, Inc | Substituted beta-lactams |
| US7705001B2 (en) * | 2008-03-18 | 2010-04-27 | Allergan, Inc | Therapeutic substituted gamma lactams |
| CA2733247C (en) * | 2008-08-14 | 2018-04-03 | Beta Pharma Canada Inc. | Heterocyclic amide derivatives as ep4 receptor antagonists |
| WO2010116270A1 (en) | 2009-04-10 | 2010-10-14 | Pfizer Inc. | Ep2/4 agonists |
| EP2488168A1 (en) | 2009-10-14 | 2012-08-22 | Gemmus Pharma Inc. | Combination therapy treatment for viral infections |
| PL2545917T3 (pl) * | 2010-03-08 | 2017-01-31 | Kaken Pharmaceutical Co., Ltd. | Nowy agonista EP4 |
| CA2738045C (en) | 2010-05-28 | 2019-02-19 | Simon Fraser University | Conjugate compounds, methods of making same, and uses thereof |
| EP2397141A1 (en) * | 2010-06-16 | 2011-12-21 | LEK Pharmaceuticals d.d. | Process for the synthesis of beta-amino acids and derivatives thereof |
| US8697057B2 (en) | 2010-08-19 | 2014-04-15 | Allergan, Inc. | Compositions and soft tissue replacement methods |
| EP2675491A2 (en) | 2011-02-17 | 2013-12-25 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
| EP2678022A2 (en) | 2011-02-23 | 2014-01-01 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
| EP2814527A1 (en) | 2012-02-16 | 2014-12-24 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
| EP2814482A1 (en) | 2012-02-16 | 2014-12-24 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
| EP2814526B1 (en) | 2012-02-16 | 2016-11-02 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
| WO2013123272A1 (en) | 2012-02-16 | 2013-08-22 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
| JP6141430B2 (ja) * | 2012-07-19 | 2017-06-07 | ケイマン ケミカル カンパニー， インコーポレーテッド | Ｅｐ４介在性骨関連疾患及び病態用ジフルオロラクタム組成物 |
| US20150272874A1 (en) | 2012-10-29 | 2015-10-01 | Cardio Incorporated | Pulmonary disease-specific therapeutic agent |
| WO2014144610A1 (en) | 2013-03-15 | 2014-09-18 | Cayman Chemical Company, Inc. | Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions |
| WO2014144500A2 (en) | 2013-03-15 | 2014-09-18 | Cayman Chemical Company, Inc. | Methods of synthesizing a difluorolactam analog |
| AU2014228973B2 (en) | 2013-03-15 | 2018-11-08 | Cayman Chemical Company, Inc. | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions |
| US10729810B2 (en) | 2013-07-19 | 2020-08-04 | Cayman Chemical Company, Inc | Methods, systems, and compositions for promoting bone growth |
| EP3030252B1 (en) | 2013-08-09 | 2018-11-07 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| WO2015056504A1 (ja) | 2013-10-15 | 2015-04-23 | 小野薬品工業株式会社 | 薬剤溶出性ステントグラフト |
| US9650414B1 (en) | 2014-05-30 | 2017-05-16 | Simon Fraser University | Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof |
| CA2953218A1 (en) | 2014-06-06 | 2015-12-10 | Allergan, Inc. | Ep4 agonists as therapeutic compounds |
| US9540357B1 (en) | 2014-07-31 | 2017-01-10 | Allergan, Inc. | 15-aryl prostaglandins as EP4 agonists, and methods of use thereof |
| CA2988523A1 (en) | 2015-06-12 | 2016-12-15 | Simon Fraser University | Amide-linked ep4 agonist-bisphosphonate compounds and uses thereof |
| CN107011377B (zh) * | 2017-05-03 | 2019-02-26 | 南通书创药业科技有限公司 | 一种β-羰基磷酸酯的制备方法 |
| PT3733665T (pt) | 2017-12-25 | 2022-10-21 | Asahi Kasei Pharma Corp | Compostos contendo unidade de 2-oxo-1,3,4-tiadiazinan-3-ilo com atividade agonista do recetor ep4 |
| US20200368223A1 (en) | 2019-05-21 | 2020-11-26 | Ardelyx, Inc. | Methods for inhibiting phosphate transport |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1158163A (en) | 1966-06-15 | 1969-07-16 | Berk Ltd | Improvements in or relating to Polymer Compositions |
| ZA72645B (en) * | 1971-03-05 | 1972-11-29 | Upjohn Co | Prostaglandin analogs |
| DE2346706A1 (de) * | 1973-09-17 | 1975-04-03 | Hoechst Ag | Neue, nicht natuerlich vorkommende analoga von prostansaeuren und verfahren zu ihrer herstellung |
| US3975399A (en) | 1974-08-06 | 1976-08-17 | E. I. Du Pont De Nemours And Company | 1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones |
| US4113873A (en) | 1975-04-26 | 1978-09-12 | Tanabe Seiyaku Co. Ltd. | 8-azaprostanoic acid derivatives |
| NL7604330A (nl) | 1975-04-28 | 1976-11-01 | Syntex Inc | Werkwijze voor de bereiding van 8-azaprostaan- zuurderivaten. |
| DE2528664A1 (de) | 1975-06-27 | 1977-01-13 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
| IL49325A (en) | 1976-03-31 | 1979-11-30 | Labaz | 8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them |
| DE2619638A1 (de) | 1976-05-04 | 1977-11-17 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
| CA1077948A (en) * | 1976-08-06 | 1980-05-20 | Albin J. Nelson | 1,-5 disubstituted-2-pyrrolidones and processes for their production |
| US4177346A (en) * | 1976-08-06 | 1979-12-04 | Pfizer Inc. | 1,5-Disubstituted-2-pyrrolidones |
| US4320136A (en) | 1980-08-11 | 1982-03-16 | E. I. Du Pont De Nemours And Company | 8-Aza-16,16-difluoroprostanoids |
| US4456613A (en) | 1982-12-27 | 1984-06-26 | E. I. Du Pont De Nemours And Company | 6-Keto- and 6-hydroxy-8-azaprostanoids and anti-ulcer use thereof |
| TW288010B (da) | 1992-03-05 | 1996-10-11 | Pfizer | |
| SE9302334D0 (sv) | 1993-07-06 | 1993-07-06 | Ab Astra | New compounds |
| ZA944647B (en) | 1993-07-06 | 1995-01-06 | Astra Ab | Novel (1-phenyl-1-heterocyclyl)methanol and (1-phenyl-1-heterocyclcl)methylamine derivatives |
| US5955481A (en) | 1994-03-28 | 1999-09-21 | Nissan Chemical Industries, Ltd. | Pyridine type thiazolidines |
| TW420669B (en) | 1994-03-28 | 2001-02-01 | Nissan Chemical Ind Ltd | Pyridine type thiazolidines |
| US5703108A (en) * | 1996-02-28 | 1997-12-30 | Pfizer Inc. | Bone deposition by certain prostaglandin agonists |
| EP1121133A1 (en) * | 1998-10-15 | 2001-08-08 | Merck & Co., Inc. | Methods for stimulating bone formation |
| AU1444200A (en) | 1998-10-15 | 2000-05-01 | Merck & Co., Inc. | Methods for inhibiting bone resorption |
| BR0016560A (pt) * | 1999-12-22 | 2002-09-10 | Pfizer Prod Inc | Agonistas seletivos do receptor ep4 no tratamento da osteoporose |
| PT1132086E (pt) * | 2000-01-31 | 2006-09-29 | Pfizer Prod Inc | Utilizacao de agonistas selectivos para o receptor da prostaglandina (pge2) 4 (ep4) para o tratamento de falha renal aguda e cronica |
| US20010056060A1 (en) * | 2000-02-07 | 2001-12-27 | Cameron Kimberly O. | Treatment of osteoporsis with EP2/EP4 receptor selective agonists |
| SK5562003A3 (en) * | 2000-11-27 | 2004-08-03 | Pfizer Prod Inc | EP4 receptor selective agonists in the treatment of osteoporosis |
| US6573294B1 (en) * | 2002-05-14 | 2003-06-03 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
-
2001
- 2001-11-05 SK SK556-2003A patent/SK5562003A3/sk not_active Application Discontinuation
- 2001-11-05 IL IL15536801A patent/IL155368A0/xx unknown
- 2001-11-05 BR BR0115687-0A patent/BR0115687A/pt not_active Withdrawn
- 2001-11-05 EP EP01978757A patent/EP1339678B1/en not_active Expired - Lifetime
- 2001-11-05 DE DE60130675T patent/DE60130675T2/de not_active Expired - Fee Related
- 2001-11-05 CN CNA018194877A patent/CN1476429A/zh active Pending
- 2001-11-05 CA CA002429850A patent/CA2429850C/en not_active Expired - Fee Related
- 2001-11-05 AT AT01978757T patent/ATE374182T1/de not_active IP Right Cessation
- 2001-11-05 JP JP2002544404A patent/JP3984164B2/ja not_active Expired - Lifetime
- 2001-11-05 EA EA200300379A patent/EA200300379A1/ru unknown
- 2001-11-05 DK DK01978757T patent/DK1339678T3/da active
- 2001-11-05 AU AU2002210848A patent/AU2002210848A1/en not_active Abandoned
- 2001-11-05 WO PCT/IB2001/002073 patent/WO2002042268A2/en active IP Right Grant
- 2001-11-05 HU HU0400807A patent/HUP0400807A2/hu unknown
- 2001-11-05 PL PL01362030A patent/PL362030A1/xx not_active Application Discontinuation
- 2001-11-05 PT PT01978757T patent/PT1339678E/pt unknown
- 2001-11-05 CZ CZ20031257A patent/CZ20031257A3/cs unknown
- 2001-11-05 SI SI200130776T patent/SI1339678T1/sl unknown
- 2001-11-05 KR KR10-2003-7007109A patent/KR20030053063A/ko not_active Application Discontinuation
- 2001-11-05 NZ NZ525164A patent/NZ525164A/en unknown
- 2001-11-05 OA OA1200300141A patent/OA12533A/en unknown
- 2001-11-05 ES ES01978757T patent/ES2291361T3/es not_active Expired - Lifetime
- 2001-11-05 EE EEP200300246A patent/EE200300246A/xx unknown
- 2001-11-05 MX MXPA03004623A patent/MXPA03004623A/es active IP Right Grant
- 2001-11-21 US US09/990,556 patent/US6552067B2/en not_active Expired - Fee Related
- 2001-11-23 HN HN2001000266A patent/HN2001000266A/es unknown
- 2001-11-23 UY UY27038A patent/UY27038A1/es not_active Application Discontinuation
- 2001-11-26 AR ARP010105489A patent/AR035074A1/es unknown
- 2001-11-26 TW TW093115078A patent/TW200424170A/zh unknown
- 2001-11-26 PE PE2001001180A patent/PE20020637A1/es not_active Application Discontinuation
- 2001-11-26 SV SV2001000746A patent/SV2003000746A/es unknown
- 2001-11-26 TN TNTNSN01166A patent/TNSN01166A1/fr unknown
- 2001-11-27 PA PA20018533901A patent/PA8533901A1/es unknown
- 2001-11-27 GT GT200100238A patent/GT200100238A/es unknown
- 2001-11-27 GT GT200100238AK patent/GT200100238AA/es unknown
-
2002
- 2002-12-20 US US10/326,366 patent/US6747054B2/en not_active Expired - Fee Related
-
2003
- 2003-04-03 BG BG107697A patent/BG107697A/xx unknown
- 2003-04-10 IS IS6775A patent/IS6775A/is unknown
- 2003-04-10 ZA ZA200302803A patent/ZA200302803B/en unknown
- 2003-05-13 MA MA27159A patent/MA26961A1/fr unknown
- 2003-05-26 NO NO20032360A patent/NO20032360L/no not_active Application Discontinuation
- 2003-05-27 EC EC2003004623A patent/ECSP034623A/es unknown
- 2003-09-23 US US10/668,633 patent/US7192979B2/en not_active Expired - Fee Related
-
2007
- 2007-05-11 JP JP2007127062A patent/JP2007197467A/ja active Pending
- 2007-11-06 CY CY20071101420T patent/CY1106976T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20032360D0 (no) | EP4 reseptor selektive agonister for behandling av osteoporose | |
| NO20022925L (no) | EP4 reseptor selektive agonister for behandling av osteoporose | |
| IS6785A (is) | EP4 viðtakahindrar til meðhöndlunar á liðagigt | |
| CY2017020I2 (el) | Στεροειδη ως αγωνιστες για τους υποδοχεις fxr | |
| NO20034122L (no) | Sammensmeltede pyridinderivater for anvendelse som vanilloidreseptorantagonister for behandling av smerte | |
| DK1446379T3 (da) | Arylanilin-beta2-adrenergiske receptoragonister | |
| NO20030213D0 (no) | Anvendelse av D2/D3 reseptor-agonister for behandling av fibromyalgi | |
| CY2007029I1 (el) | Μεθοδος για την παρασκευη υποκατεστημενων οκτανοϋλ-αμιδιων | |
| NO20016246L (no) | Selektiv iGluR5 reseptorantagonist for behandling av migrene | |
| DK1764111T3 (da) | Vaginalt indgivne anti-dysrytmi midler til behandling af uterin dysrytmi | |
| NO20020574D0 (no) | Substituerte 1,5-dihydropyrrol-2-onderivater som er virksomme som NMDA-reseptorantagonister for behandlingen av smertetilstanden | |
| EP1121939A3 (en) | Treatment of osteoporosis with EP2/EP4 receptor selective agonists | |
| EP1287404A4 (en) | METHOD FOR IMMOBILIZING OLIGONUCLEOTIDES USING THE CYCLOADDITION BIKONJUGATION METHOD | |
| NO20032304D0 (no) | Anvendelse av selektive dopamin D4-reseptoragonister for behandling av seksuell dysfunksjon | |
| HK1059782A1 (en) | Indole derivatives useful for the treatment of cnsdisorders | |
| NO20022142D0 (no) | Anvendelse av dopamin-D3 reseptor agonister for behandling av saltavhengig hypertensjon | |
| FI5227U1 (fi) | Laitteisto laastin jakelemiseksi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |